Pharmasyntez places second Paclical order with Oasmia for $7.5 million

US oncology specialist Oasmia Pharmaceutical (Nasdaq: OASM) has announced that Pharmasyntez, its distribution partner in Russia and the Commonwealth of Independent States, has placed its second order for Paclical (paclitaxel) to a value of $7.5 million.

This follows the first order to this market for $1.5 million in end-user value, bringing the total of the end-user sales value to over $9 million in commercial orders in one week.

Julian Alexov, executive chairman of Oasmia, said: "We are thrilled that Paclical has been so well received in Russia and CIS. These positive initial orders are a reflection of the market's confidence in the product. We are confident in imminent sales growth as the product continues to garner interest for its ability to enable higher doses, shorten infusion time, eliminate the need for pre-medication and improve the safety profile for patients compared to the available standard treatments."